Axoltis Pharma

Axoltis Pharma raises €18 million to accelerate development of Amyotrophic Lateral Sclerosis (ALS) drug candidate

2 December 2025 -- Clermont-Ferrand, France -- Axoltis Pharma, a biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announces the closing of a Series A funding round worth €18 million ($20.9M), to be disbursed in two installments. The funding, which includes new and historic investors, will enable the company to pursue the...
15 – 17, Rue du Pré la Reine, 63100 Clermont-Ferrand

+33 (0)472 621 736